Advancing Liquid Biopsy Diagnostics: Simultaneous Profiling of Protein and miR Biomarkers for Drug-Induced Liver Injury with COMBO LiverAce.

Drug-Induced Liver Injury (DILI) is a severe adverse event associated with substantial
health risks and drug withdrawals, particularly in patients undergoing highly cytotoxic
chemotherapies. Recent multinational initiatives have identified protein and microRNA
(miRNA) biomarkers for early detection and mechanistic understanding of DILI. This
study presents the groundbreaking " COMBO LiverAce" assay, which integrates
dynamic chemical labelling with Luminex xMAP technology.
COMBO LiverAce enables versatile multiplexing, simultaneously analysing proteins and
miRNAs in patient serum samples. It is the first assay capable of profiling both protein
and miRNA biomarkers for DILI diagnosis in a single step. By integrating dynamic
chemical labelling with Luminex xMAP technology, COMBO LiverAce provides an
innovative and comprehensive solution for assessing DILI.
This assay has the potential to revolutionise liquid biopsy in the diagnosis and
monitoring of DILI. Simultaneous interrogation of protein and miRNA biomarkers
improves efficiency, cost-effectiveness, and diagnostic accuracy. COMBO LiverAce
facilitates early detection, risk assessment, and personalised treatment strategies for
DILI patients.
This study highlights the development, validation, and potential applications of
LiverAce COMBO, underscoring its significance in advancing liquid biopsy techniques
for DILI but also other diseases, including cancer. The integration of dynamic chemical
labelling with Luminex xMAP technology in LiverAce COMBO opens new avenues for
improved diagnosis and management of these conditions, offering promising prospects
for personalised patient care.